Medical Health Cluster


REGEN-COV™ (casirivimab with imdevimab) has been granted an Emergency Use Authorization by the U.S. Food and Drug Administration

The development and manufacturing of casirivimab and imdevimab has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) under OT number: […]

Read More